- Home
- CRON vs PRAX Comparison
CRON vs PRAX Comparison
Compare CRON & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- PRAX
- Stock Information
- Founded
- CRON N/A
- PRAX 2015
- Country
- CRON Canada
- PRAX United States
- Employees
- CRON N/A
- PRAX N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CRON Health Care
- PRAX Health Care
- Exchange
- CRON Nasdaq
- PRAX Nasdaq
- Market Cap
- CRON 809.4M
- PRAX 950.8M
- IPO Year
- CRON N/A
- PRAX 2020
- Fundamental
- Price
- CRON $2.69
- PRAX $45.71
- Analyst Decision
- CRON
- PRAX Strong Buy
- Analyst Count
- CRON 0
- PRAX 9
- Target Price
- CRON N/A
- PRAX $94.44
- AVG Volume (30 Days)
- CRON 2.8M
- PRAX 383.5K
- Earning Date
- CRON 11-11-2025
- PRAX 11-05-2025
- Dividend Yield
- CRON N/A
- PRAX N/A
- EPS Growth
- CRON N/A
- PRAX N/A
- EPS
- CRON 0.05
- PRAX N/A
- Revenue
- CRON $130,282,000.00
- PRAX $7,765,000.00
- Revenue This Year
- CRON $19.67
- PRAX N/A
- Revenue Next Year
- CRON $30.56
- PRAX $22.22
- P/E Ratio
- CRON $53.27
- PRAX N/A
- Revenue Growth
- CRON 28.01
- PRAX 338.45
- 52 Week Low
- CRON $1.60
- PRAX $26.70
- 52 Week High
- CRON $2.77
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- CRON 64.73
- PRAX 52.84
- Support Level
- CRON $2.50
- PRAX $37.25
- Resistance Level
- CRON $2.63
- PRAX $40.69
- Average True Range (ATR)
- CRON 0.09
- PRAX 2.52
- MACD
- CRON -0.00
- PRAX 0.30
- Stochastic Oscillator
- CRON 90.00
- PRAX 78.96
About CRON Cronos Group Inc. Common Share
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.